Literature DB >> 19428866

T-cell vaccines that elicit effective immune responses against HCV in chimpanzees may create greater immune pressure for viral mutation.

I Zubkova1, Y H Choi, E Chang, K Pirollo, T Uren, H Watanabe, F Wells, A Kachko, K Krawczynski, M E Major.   

Abstract

A prime/boost vaccine strategy that transfects antigen-presenting cells using ligand-modified immunoliposomes to efficiently deliver plasmid DNA, followed by boosting with non-replicating recombinant adenovirus was used in chimpanzees to generate HCV-specific memory T-cells. Three chimpanzees (two vaccines, one control) were immunized with immunoliposomes complexed with DNA expressing NS3-NS5B or complexed with empty vector. Animals were boosted with adenovirus expressing NS3-NS5B, or non-recombinant adenovirus (control). Using liposome delivery we were able to obtain specific HCV responses following DNA priming in the chimpanzees. This data and mouse immunization studies confirm this as a more efficient delivery system than direct intramuscular inoculations with naked DNA. Subsequent to the adenovirus boost significant increases in peripheral HCV-specific T-cell responses and intrahepatic IFN-gamma and CD3varepsilon mRNA were also observed in the two vaccinated animals. Following challenge (100 CID(50)) both vaccinated animals showed immediate and significant control of viral replication (peak titers 3.7x10(4) and 9x10(3)IU/mL at weeks 1 and 2), which coincided with increases in HCV-specific T-cell responses. Viral kinetics in the control animal were comparable to historical controls with exponential increases in titer during the first several weeks. One vaccinated animal developed a low-level persistent infection (2x10(3)IU/mL) which correlated with a decrease in HCV-specific T-cell responses. Circulating virus isolated from both vaccinated animals showed approximately 2-fold greater nonsynonymous mutation rates compared to controls and the nonsynonymous/synonymous mutation rate ratio was indicative of positive selection. These data suggest that although T-cell vaccines can induce immune responses capable of controlling HCV, they also induce high levels of immune pressure for the potential selection of escape mutants.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19428866     DOI: 10.1016/j.vaccine.2009.02.045

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  15 in total

1.  Meta-analysis of hepatitis C virus vaccine efficacy in chimpanzees indicates an importance for structural proteins.

Authors:  Harel Dahari; Stephen M Feinstone; Marian E Major
Journal:  Gastroenterology       Date:  2010-06-02       Impact factor: 22.682

Review 2.  Adaptive immunity to the hepatitis C virus.

Authors:  Christopher M Walker
Journal:  Adv Virus Res       Date:  2010       Impact factor: 9.937

3.  Hepatitis C virus clearance correlates with HLA-DR expression on proliferating CD8+ T cells in immune-primed chimpanzees.

Authors:  Iryna Zubkova; Hongying Duan; Frances Wells; Howard Mostowski; Esther Chang; Kathleen Pirollo; Kris Krawczynski; Robert Lanford; Marian Major
Journal:  Hepatology       Date:  2014-01-28       Impact factor: 17.425

4.  Synthetic vaccines: Immunity without harm.

Authors:  Abhinav P Acharya; Niren Murthy
Journal:  Nat Mater       Date:  2011-03       Impact factor: 43.841

Review 5.  Immune mechanisms of vaccine induced protection against chronic hepatitis C virus infection in chimpanzees.

Authors:  Babs E Verstrepen; André Boonstra; Gerrit Koopman
Journal:  World J Hepatol       Date:  2015-01-27

6.  Amino acid residue-specific neutralization and nonneutralization of hepatitis C virus by monoclonal antibodies to the E2 protein.

Authors:  Hongying Duan; Alla Kachko; Lilin Zhong; Evi Struble; Shivani Pandey; Hailing Yan; Christine Harman; Maria Luisa Virata-Theimer; Lu Deng; Zhong Zhao; Marian Major; Stephen Feinstone; Pei Zhang
Journal:  J Virol       Date:  2012-09-12       Impact factor: 5.103

Review 7.  Will there be a vaccine to prevent HCV infection?

Authors:  Jonathan R Honegger; Yan Zhou; Christopher M Walker
Journal:  Semin Liver Dis       Date:  2014-04-29       Impact factor: 6.115

Review 8.  Emerging concepts in immunity to hepatitis C virus infection.

Authors:  Hugo R Rosen
Journal:  J Clin Invest       Date:  2013-10-01       Impact factor: 14.808

9.  Prophylactic and Therapeutic Vaccination against Hepatitis C Virus (HCV): Developments and Future Perspectives.

Authors:  Marian E Major
Journal:  Viruses       Date:  2009-08-12       Impact factor: 5.048

10.  Ethanol and reactive species increase basal sequence heterogeneity of hepatitis C virus and produce variants with reduced susceptibility to antivirals.

Authors:  Scott Seronello; Jessica Montanez; Kristen Presleigh; Miriam Barlow; Seung Bum Park; Jinah Choi
Journal:  PLoS One       Date:  2011-11-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.